Description
REOB ALL FUNDS TO CURRENT DELIVERY/TASK ORDER WITH INSTRUCTIONS FOR BILLING AND ORDER ADMINISTRATION BY A THIRD-PARTY VENDOR
Base award description: QTY: 2, TAKHZYRO 150MG/ML SYRINGE 2ML PER SYRINGE NDC: 47783-0646-01
Modification chain · 3 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2023-10-30+$36,102= $36,102
- Mod P000012023-10-30-$36,102= $0
- Mod P000022023-10-31+$36,102= $36,102
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2023-10-30 | +$36,102 | $36,102 | QTY: 2, TAKHZYRO 150MG/ML SYRINGE 2ML PER SYRINGE NDC: 47783-0646-01 |
| Mod P00001· FUNDING ONLY ACTION | 2023-10-30 | −$36,102 | $0 | DEOB ALL FUNDS TO RECOUP FUNDS TO CREATE A NEW DELIVERY ORDER BECAUSE VENDOR USES A THIRD-PARTY VENDOR FOR BI… |
| Mod P00002· FUNDING ONLY ACTION | 2023-10-31 | +$36,102 | $36,102 | REOB ALL FUNDS TO CURRENT DELIVERY/TASK ORDER WITH INSTRUCTIONS FOR BILLING AND ORDER ADMINISTRATION BY A THI… |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI DDEVYUAXJ624)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24526N0840 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $19,139 | FY2026 |
| 36E79726A0023 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
| 36C24526N0835 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $34,605 | FY2026 |
| 36F79726D0181 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
| 36C26026P0420 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $107,540 | FY2026 |
| 36C26126P0581 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $27,250 | FY2026 |
Other recipients under 6505 from 249-NETWORK CONTRACT OFFICE 9 (36C249) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C24926N0676 | AMICUS THERAPEUTICS US, LLC | 249-NETWORK CONTRACT OFFICE 9 (36C249) | $68,519 | FY2026 |
| 36C24926N0651 | BRISTOL-MYERS SQUIBB COMPANY | 249-NETWORK CONTRACT OFFICE 9 (36C249) | $378,650 | FY2026 |
| 36C24926N0658 | BRISTOL-MYERS SQUIBB COMPANY | 249-NETWORK CONTRACT OFFICE 9 (36C249) | $364,139 | FY2026 |
| 36C24926N0590 | BRISTOL-MYERS SQUIBB COMPANY | 249-NETWORK CONTRACT OFFICE 9 (36C249) | $364,139 | FY2026 |
| 36C24926N0589 | BRISTOL-MYERS SQUIBB COMPANY | 249-NETWORK CONTRACT OFFICE 9 (36C249) | $364,139 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C24924N0162_3600_V797D50492_3600 · retrieved 2026-09-26.